The Motley Fool

The Avacta share price has exploded in the past year. Here’s what I’m doing now

Image source: Getty Images

Avacta (LSE:AVCT) is a pharmaceutical firm trying to combat the Covid-19 pandemic. The Avacta share price has exploded in the past 12 months. Based on this rise, I want to know if the FTSE AIM-listed share is a good investment for my portfolio.

Avacta share price rise

Avacta is a small biotech firm with two core proprietary platforms. Due to its size, it often partners up with larger, better known pharma giants who need its proprietary platforms.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

One of Avacta’s Covid-19-related partnerships is with Cytiva. Avacta has also recently signed a distribution agreement with Medusa Ltd for direct-to-consumer sales of its Covid-19-related products.

Last March, the Avacta share price was trading for close to 20p per share. As I write, shares are currently trading for close to 240p per share. This is close to a mammoth 1,000% increase! I believe Avacta’s foray into Covid-19-related products have caused its share price to explode and remain higher than pre-Covid-19 levels. 

Recent activity and performance

After Avacta’s initial announcement that it was attempting to produce Covid-19-related testing kits, it has made good progress. August saw it ready for clinical trials. A month later, manufacturing capacity was expanded. And a few short weeks later, it made a research kit available for other pharma firms too.

Just last month, Avacta announced that its preliminary results from trials showed over 96% accuracy in identifying Covid-19 in patients. This is a very high figure that I believe has helped maintain Avacta’s share price at this new higher level compared to last year.

Avacta is now pursuing a full clinical approval to launch within the EMEA region before the end of the first quarter of 2021. The Covid-19 pandemic does not seem to be going away, therefore many millions of tests could be needed over the coming months and perhaps years.

A business update at the end of February highlighted Avacta’s progress for its Covid-19 test kit as well as its other product pipeline. Avacta’s cash position was strengthened in its recent report. FY results are expected next month.

What I’m doing now

The Avacta share price has experienced a positive rise since the pandemic began and markets crashed. I have three issues with the Avacta share price. Firstly, is its high valuation. Forecasted revenue for its full-year ending 2021 compared to its current market cap of £689m reveals a price-to-sales ratio of close to 86 which is too high for me.

Next, if regulatory approval is not received, the Avacta share price could fall back to pre-crash levels and set it back. Finally, competition also makes me feel uneasy about Avacta’s longer-term prospects. There are bigger and more experienced pharmaceutical firms producing their own similar solutions that could trump Avacta’s.

Overall, if I invested in Avacta a year ago, I would be happy right now. Hindsight is a wonderful thing, however. Right now, I cannot justify to myself buying shares in Avacta based on the reasons above but I will keep an eye on developments. Here is a stock I do like right now and I believe it could be a good addition to my portfolio.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.